Eisai 和 Biogen 研发的阿尔茨海默症药物在大型试验中显示减缓病情发展

Zhitong
2022.09.28 01:15
Eisai Co.和合作伙伴 Biogen Inc.表示，他们研发的阿尔茨海默症治疗药物 lecanemab 减缓了这种疾病的发展，成为第一款在最后阶段试验中明显抑制阿尔茨海默症发展的药物。据两家公司发布的声明，与使用共同评级量表的安慰剂相比，这款药物在 18 个月内使早期阿尔茨海默症患者的认知下降速度减缓了 27％，达到了试验的主要目标。虽然作用影响温和，但达到高度统计学显著性。
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.